

Notice of References Cited	Application/Control No. 10/550,154		Applicant(s)/Patent Under Reexamination GRIND	
	Examiner MAURY AUDET		Art Unit 1654	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2003/0077229	04-2003	Dugger, Harry A. III	424/43
*	B	US-2005/0069527 A1	03-2005	Laughlin et al.	424/093.7
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
*	N	WO 02/36157	05-2002	WO	Astrazeneca	A61K 38/55
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
*	U	http://en.wikipedia.org/wiki/Warfarin (last modified on 20 September 2009).
*	V	"The Complete Drug Reference" (as cited by the Applicant in the Remarks filed January 04, 2007).
*	W	KRALOVA ET AL."The importance of biochemical changes for the diagnosis of active coronary artery sclerosis", 1963, Vnitřní Lekarství, Vol. 8. Pages 974-982
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.